|Other Names||Krueppel-like factor 15, Kidney-enriched krueppel-like factor, KLF15, KKLF|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional regulator that binds to the GA element of the CLCNKA promoter. Binds to the KCNIP2 promoter and regulates KCNIP2 circadian expression in the heart (By similarity). Is a repressor of CTGF expression, involved in the control of cardiac fibrosis. It is also involved in the control of cardiac hypertrophy acting through the inhibition of MEF2A and GATA4 (By similarity). Involved in podocyte differentiation (By similarity). Inhibits MYOCD activity. Is a negative regulator of TP53 acetylation. Inhibits NF-kappa-B activation through repression of EP300-dependent RELA acetylation.|
|Tissue Location||Highly expressed in liver, skeletal muscle, and kidney. Expressed in cardiomyocytes. Expression is highly reduced in cardiac tissue of patients with non-ischemic cardiomyopathy and aortic aneurysm, and in glomerular disease. Not expressed in bone marrow or lymphoid tissues|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
KLF15 is a transcriptional activator. Binds to the GA element of the CLCNKA promoter.
Yamamoto, K., et al. Biochem. Biophys. Res. Commun. 400(1):175-180(2010)Haldar, S.M., et al. Sci Transl Med 2 (26), 26RA26 (2010) :Li, J., et al. BMC Genet. 11, 12 (2010) :Du, X., et al. J. Clin. Endocrinol. Metab. 94(7):2594-2601(2009)Wang, B., et al. J. Mol. Cell. Cardiol. 45(2):193-197(2008)
If you have any additional inquiries please email technical services at email@example.com.